How Much Does MEDVi Cost? GLP-1 Pricing Guide (2026)
What MEDVi charges for GLP-1 care at signup, what that price becomes after the intro period and at a higher dose, how it stacks against Wegovy and Zepbound self-pay, and which details MEDVi leaves unpublished.
MEDVi's GLP-1 weight loss program starts at $179 a month, the rate recorded in our provider database on August 21, 2026 and matched by independent pricing reports. That lands it in the middle of the compounded-GLP-1 field: under Sprout Health and SkinnyRx, above Strut Health and HealthRx, dead even with TrimRx. MEDVi's own site does spell out its compounded status: the $179 plan is compounded medication, compounded and filled by the partner pharmacies MEDVi names on its site (Triad Rx, RedRock Pharmacy, and Beaker Pharmacy) rather than by MEDVi itself, and not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality. What it does not spell out is whether your specific plan runs on semaglutide or tirzepatide, or whether you are on the separate brand-name path instead. Two questions this page answers: where $179 actually sits next to MEDVi's peers, and what it turns into after an intro period, after a dose increase, and against paying for Wegovy or Zepbound directly. Confirm both your exact medication and your price at signup. The headline number alone guarantees neither.
Average Costs Comparison
MEDVi's $179/month starting price sits in the middle of the compounded-GLP-1 field we track. The five other compounded-GLP-1 providers we benchmark land on either side of it, at entry prices we last verified on August 21, 2026. None of the compounded products in this table is FDA-approved or reviewed by the FDA for safety, effectiveness, or quality; the FDA-approved brand options are priced further down the page:
| Provider | Monthly Cost | Per Dose | Consultation | Shipping | Notes |
|---|---|---|---|---|---|
| Strut Health | $99/month | Included | Included | The floor of this set. Every figure in this column is an entry price, not a maintenance-dose price. | |
| HealthRx | $99/month | Free online intake per its listing | Free, 24-48 hours | The $99 figure is its 12-month-plan rate; its own listing puts a 3-month plan at $133/month. Compounded semaglutide and tirzepatide either way, so neither carries FDA approval. | |
| MEDVi | $179/month | Not itemized in MEDVi's listing | Ships to your door, cost not broken out | Free dietician visits and care coaching included with your plan. The $179 plan is compounded medication, compounded and filled by MEDVi's named partner pharmacies rather than by MEDVi itself; compounded GLP-1s are not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality. | |
| TrimRx | $179/month | Included | Included | Ties MEDVi exactly at the entry number. | |
| Sprout Health | $199/month | Not published | Refrigerated shipping from a US pharmacy | Compounded semaglutide and tirzepatide, dosed by US-licensed clinicians per its listing; the compounded products it fills sit outside FDA approval and FDA review. | |
| SkinnyRx | $199/month | Not published | Not published | Shares the top of this compounded set with Sprout Health, and both still sit below every brand-name standard self-pay rate further down this page. SkinnyRx also lists FDA-approved Wegovy at brand pricing. |
Top Weight Loss Providers by Value
GLP-1 Weight Loss From $179/mo - Free 2-Minute Assessment
- Compounded GLP-1 (semaglutide) from $179/mo, GLP-1 + GIP (tirzepatide) from $259/mo
- Brand-name Ozempic®, Mounjaro®, Zepbound® and Wegovy® also available
- Free 2-minute qualification quiz and FREE doctor consultation - no cost, no obligation
- Free tracked shipping straight to your door after approval
Doctor-Guided GLP-1 From $179/mo - Free Dietician Visits Included
- Doctor-guided GLP-1 care, 100% online - no waiting rooms
- Free dietician visits and care coaching included with your plan
- Doctor-formulated plans adjusted as your body responds
- Fast, discreet shipping to your door
Free Insurance Check - Zepbound® & Wegovy® 100% Online
- Full GLP-1 suite: Zepbound®, Wegovy® pill and pen, semaglutide and more
- Free insurance check shows what your plan covers before you pay
- Tirzepatide (Zepbound®) averaged up to 20.9% body weight loss in the 72-week SURMOUNT-1 trial; individual results vary
- On-demand provider coaching and support, 100% online
Month One, Month Two, and Your Maintenance Dose
Your First Month
MEDVi's entry price is $179/month, the figure recorded in our provider database on August 21, 2026. It's the number most comparison pages cite, ours included, and independent pricing reports put a MEDVi first month at the same figure.
After Your Intro Period
MEDVi's own pricing page is quiz-gated, so there is no published figure to read. Independent third-party pricing reports describe a step-up to roughly $299/month once an introductory period ends. MEDVi's own hero pricing on our site separately lists a $179-$299/mo range, which lines up with that pattern. Treat $299/month as a realistic steady-state estimate, not a confirmed number - ask MEDVi directly what your price becomes after month one.
If Your Dose Increases
Across the industry, compounded GLP-1 programs commonly raise your price as they raise your dose during titration, the slow ramp-up that usually runs across your first 2-4 months. MEDVi does not publish a maximum-dose price on its own site. Ask what the top-tier dose costs before you commit, the same way you would with any compounding provider, none of whose compounded products carry FDA approval.
Where Insurance Stops and Your HSA Card Starts
Commercial insurance rarely pays for MEDVi, but your HSA or FSA card generally can, because this is a prescribed medication rather than a supplement. That prescription status is what changes the math, with one catch that applies specifically to compounded medications.
Commercial Insurance
Coverage: Rarely covers the medication cost directly
Most commercial plans that cover GLP-1s cover the brand-name drug (Wegovy, Zepbound) under a specific prior-authorization pathway, not a compounded version filled through a telehealth-affiliated pharmacy. MEDVi does not publish an insurance-billing option anywhere on its site - budget as a cash-pay program.
Medicare / Medicaid
Coverage: Not typically covered
Neither program broadly covers GLP-1 medications for weight loss as of August 2026, regardless of provider.
HSA/FSA
Coverage: Generally eligible
Because this is a prescribed medication (not a supplement), it generally qualifies for HSA/FSA reimbursement the way most prescription drugs do. Confirm with your plan administrator, since compounded-specific exclusions exist on some plans.
MEDVi vs. Paying for Wegovy or Zepbound Directly
MEDVi's program is compounded medication, compounded and filled by its named partner pharmacies rather than made by the brand manufacturer, and the price gap against Wegovy or Zepbound reflects that: MEDVi's own site discloses that compounded GLP-1s are not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality, while Wegovy and Zepbound are FDA-approved brands. Those two brands are also the ones carrying head-to-head trial data. In the SURMOUNT-5 trial, participants taking tirzepatide (the drug in Zepbound) lost an average of 20.2% of body weight at 72 weeks, versus 13.7% for participants taking semaglutide (the drug in Wegovy); in STEP 1, semaglutide averaged roughly 14.9%. Individual results vary, and both trials studied the FDA-approved brand products, not compounded versions of them.
| Medication | Compounded/Generic | Brand-Name | Savings |
|---|---|---|---|
| MEDVi (starting price) | Cost: $179/month, reportedly stepping up to ~$299/month after an intro period. | Compounded program, compounded and filled by MEDVi's named partner pharmacies, not by MEDVi; not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality. Specific drug not published by MEDVi. | Cheaper than NovoCare Wegovy ($349/month standard) at the starting price; the gap narrows or closes at the reported ~$299/month steady state. |
| Wegovy via NovoCare Pharmacy (self-pay) | Cost: $349/month standard dose, $399/month for the 7.2mg high dose; a $199/month introductory rate runs through December 31, 2026. | FDA-approved brand semaglutide, manufacturer self-pay channel. | NovoCare's own intro rate ($199/month) can undercut MEDVi's steady-state price - compare both before choosing. |
| Zepbound via LillyDirect (self-pay) | Cost: $299/month (2.5mg starting dose) up to $449/month (7.5mg+), as long as you refill within 45 days; $499-$699/month if you lapse. | FDA-approved brand tirzepatide, manufacturer self-pay channel. | LillyDirect's starting dose ($299/month) matches MEDVi's reported steady-state price - worth comparing directly if you qualify for tirzepatide. |
How to Avoid Overpaying for MEDVi
- Your $179/month plan is compounded medication, compounded and filled by MEDVi's named partner pharmacies rather than by MEDVi itself, not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality - so ask MEDVi directly whether it's compounded semaglutide or compounded tirzepatide before you sign up, since MEDVi doesn't publish which one you get. Want the brand-name drug instead? That's a separate $99 membership plus the cost of Wegovy or Zepbound itself, with no published total for what that adds up to.
- Two numbers matter more than the headline: what you pay in month two, and what you pay at your maintenance dose. Reported steady-state pricing (~$299/month) is higher than the advertised starting price, and MEDVi does not publish a maximum-dose figure.
- Compare against NovoCare's $199/month Wegovy introductory rate (through December 31, 2026) and LillyDirect's $299/month Zepbound starting dose before assuming compounded is automatically cheaper once your dose escalates.
- Your HSA or FSA will usually cover this as a prescription, but some plans carve out compounded medications specifically. One call to your plan administrator settles it before you spend the money.
- Every price on this page is an August 2026 snapshot, and telehealth GLP-1 pricing moves fast. Check MEDVi's current number at checkout before you commit to it.
Where the Bill Can Grow After Signup
- The reported step-up after your intro period, to roughly $299/month. MEDVi does not confirm it on its published pricing page, so ask before your first renewal.
- Dose-escalation increases: your price can rise as your dose does, on a schedule MEDVi does not publish.
- Labs and follow-up visits are billed separately from the base subscription on some compounding programs. Confirm what MEDVi's $179/month actually includes.
- Cancellation timing: the renewal that ends your intro price is the one to get ahead of, so find your billing date before month one runs out.
Frequently Asked Questions
How much does MEDVi cost per month?
MEDVi's GLP-1 program starts at $179/month, a rate we last verified in our provider database on August 21, 2026. Independent pricing reports and our own comparison data suggest the price can step up to roughly $299/month after an introductory period, though MEDVi does not confirm that figure on its published page - ask directly before you sign up.
Is MEDVi's GLP-1 medication compounded or brand-name?
Both, depending on which path you take - but the $179/month plan is the compounded one, not brand-name medication. MEDVi's own site names the pharmacies that compound it (Triad Rx, RedRock Pharmacy, and Beaker Pharmacy) and discloses that compounded GLP-1s are not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality. That compounded medication may be compounded semaglutide or compounded tirzepatide - MEDVi doesn't publish which one your plan uses. Separately, MEDVi also offers a brand-name path for Wegovy or Zepbound: a $99 membership plus the cost of the medication itself, with no published total. Confirm which path and which drug you are getting before you enroll.
Does MEDVi bill insurance, or is it cash and HSA/FSA only?
Commercial insurance rarely covers MEDVi's program directly, since MEDVi does not publish an insurance-billing pathway. Budget for it as cash-pay. Your HSA or FSA is the better bet: this is a prescribed medication rather than a supplement, so it generally qualifies for reimbursement the way most prescription drugs do, though compounded-specific exclusions exist on some plans. Confirm with your plan administrator.
Does MEDVi still beat Wegovy and Zepbound self-pay after the intro period?
At its $179/month starting price, MEDVi is cheaper than NovoCare's standard $349/month Wegovy rate, though NovoCare's own $199/month introductory rate (through December 31, 2026) can undercut MEDVi. Against LillyDirect's Zepbound self-pay, MEDVi's reported ~$299/month steady-state price roughly matches LillyDirect's $299/month starting dose. Compare your actual MEDVi price after any intro period against both manufacturer self-pay options before deciding.
Sources & References
Our comparisons are informed by official sources and regulatory guidelines. We encourage readers to verify information with authoritative sources.
- FDA Drug InformationGLP-1 medication approvals and safety
- NIH National Institute of DiabetesWeight management research
- CDC Obesity InformationObesity statistics and health impacts
- Obesity Medicine AssociationClinical obesity treatment guidelines
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
Start With a Top Weight Loss Provider
GLP-1 Weight Loss From $179/mo - Free 2-Minute Assessment
- Compounded GLP-1 (semaglutide) from $179/mo, GLP-1 + GIP (tirzepatide) from $259/mo
- Brand-name Ozempic®, Mounjaro®, Zepbound® and Wegovy® also available
- Free 2-minute qualification quiz and FREE doctor consultation - no cost, no obligation
- Free tracked shipping straight to your door after approval
Doctor-Guided GLP-1 From $179/mo - Free Dietician Visits Included
- Doctor-guided GLP-1 care, 100% online - no waiting rooms
- Free dietician visits and care coaching included with your plan
- Doctor-formulated plans adjusted as your body responds
- Fast, discreet shipping to your door
Free Insurance Check - Zepbound® & Wegovy® 100% Online
- Full GLP-1 suite: Zepbound®, Wegovy® pill and pen, semaglutide and more
- Free insurance check shows what your plan covers before you pay
- Tirzepatide (Zepbound®) averaged up to 20.9% body weight loss in the 72-week SURMOUNT-1 trial; individual results vary
- On-demand provider coaching and support, 100% online
Ready to Compare Providers?
Use our cost calculator to get personalized pricing estimates based on your insurance and location.
Disclaimer: Pricing information is based on publicly available data and may change without notice. Actual costs depend on your specific treatment plan, insurance coverage, and provider. Always verify current pricing with providers before purchasing. This article is for informational purposes only and is not financial or medical advice. We may receive compensation through affiliate links, which helps support our research.
Regulatory noticeRegulatory note (verified August 22, 2026): On February 20, 2026 the FDA issued MEDVi, LLC a warning letter (MARCS-CMS 721455) citing misbranding under sections 502(a) and 502(bb) of the FD&C Act. Reviewing medvi.io in December 2025, the FDA said labels bearing "MEDVi" implied MEDVi compounds the drugs when it does not, and that "Same active ingredient as Wegovy and Ozempic" and "Same active ingredient as Mounjaro and Zepbound" implied an FDA approval compounded drugs do not have. We found no close-out letter, so the matter appears open. MEDVi states medvi.io is affiliate-operated rather than company-operated; we could not verify that, and the letter is addressed to MEDVi, LLC. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): The FDA reviewed struthealth.com in December 2025 and, on February 20, 2026, issued Strut Health, LLC a warning letter, MARCS-CMS 721448. It raises two separate problems. Pictured product labels carry the "Strut" name, which the agency said represents Strut as the compounder of the semaglutide and tirzepatide products when it is not. Three site claims are also quoted, among them "Generic Zepbound, Mounjaro" and "Semaglutide is the active ingredient in the brand medications." Because compounded drugs hold no FDA approval, the FDA said wording of that kind implies one, and it cited misbranding under sections 502(a) and 502(bb) of the FD&C Act. FDA’s warning letter index shows no response letter and no close-out letter, so we treat the matter as open. Read the FDA letter
Verification limitationVerification note (checked August 23, 2026): we could not identify the legal entity behind HealthRx through public records. Its website does not name an operating company, its domain registration is privacy-shielded, and we could not confirm a listing in any business registry or accreditation database we checked. This is not a finding of wrongdoing. It means our usual checks, including our search of FDA enforcement records, could only be run against the brand name and domain rather than a confirmed company.
Regulatory noticeRegulatory note (verified August 22, 2026): Hers is a brand of Hims & Hers Health, Inc., and the FDA wrote to that company twice on September 9, 2025, once for each brand. The Hers letter, MARCS-CMS 716825, went to chief executive Andrew Dudum after an August 2025 review of forhers.com. It quotes two claims made for compounded semaglutide: "Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." The agency’s position is that compounded products carry no FDA approval, so claims like these imply a sameness with approved medicines that has not been established, making the products misbranded. FDA’s index lists neither a response nor a close-out letter, so the matter stands open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): One sentence is all that FDA warning letter MARCS-CMS 715879 quotes. Sent to Sprout Health Partners LLC on September 9, 2025 after an August 2025 review of joinsprouthealth.com, it cites the line "GLP-1 medications are FDA-approved and backed by extensive clinical research..." Appearing on pages offering compounded semaglutide and tirzepatide, that statement implied to the agency that the compounded products themselves are FDA-approved, which they are not, and it was cited as misbranding under FD&C Act 502(a) and 502(bb). A search of FDA’s warning letter index turns up no close-out letter, so the matter appears open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): Skinny.Rx operates as SkinnyRx, but the legal entity is Lean Rx, Inc., and that is the name on FDA warning letter MARCS-CMS 717989, dated February 20, 2026. Following a December 2025 review of skinnyrx.com, the agency objected to the "SkinnyRx" name on pictured labels, saying it implies SkinnyRx compounds the drugs itself, and to three marketing lines, including "Get access to the same active ingredient as name-brand GLP-1 medications" and "It contains the same active ingredient as FDA-approved medications." Compounded semaglutide and tirzepatide are not FDA-approved, so the FDA read those lines as implying an approval that does not exist and classed the products as misbranded. No close-out letter is posted; read the matter as unresolved. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. Two lines about compounded semaglutide are quoted in it: "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." Compounded drug products are not FDA-approved, and the agency said phrasing of this sort suggests otherwise, which is what makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. No close-out letter appears in FDA’s index; treat this as open. Read the FDA letter